S. Dharia

A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.

R. Dean, K. Schuh, R. Anton, 2014, Alcoholism, clinical and experimental research.

Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women

J. Bishop, B. Fijal, J. Houston, 2011, Psychiatry Research.

Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients

R. Perlis, A. Heinloth, B. Fijal, 2010, Biological Psychiatry.

Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder

R. Perlis, B. Fijal, J. Houston, 2012, The Pharmacogenomics Journal.